
Relay Therapeutics rose 135.0% from $6.77 to $15.91, ahead of the S&P 500's +4.7%. Its worst day was Apr 28 (−12.8%), and its low came Nov 21 at $6.77.
Nov 21, 2025 – Nov 19, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Relay Therapeutics shares rose 20.7%, while the S&P 500 rose 1.5%.
+20.7%, the year's best day · S&P 500 +1.5%
Relay Therapeutics shares rose 12.0%, while the S&P 500 rose 0.4%.
+12.0% · S&P 500 +0.4%
Story events cover the past 12 months · Times ET
EPS of $-0.32 beat the $-0.39 estimate on $7.0M revenue (est. $8.6M).
+12.0% · S&P 500 −0.5%
Relay Therapeutics shares rose 16.4%, while the S&P 500 rose 0.1%.
+16.4% · S&P 500 +0.1%
Relay Therapeutics shares fell 12.8%, while the S&P 500 fell 0.5%.
−12.8%, the year's worst day · S&P 500 −0.5%
EPS of $-0.41 missed the $-0.36 estimate on $3.0M revenue (est. $6.8M).
−0.6% · S&P 500 +1.4%
Relay Therapeutics closed at its highest level of the year, 206.5% above where the year started.
+5.7% · S&P 500 +0.8%
EPS of $-0.41 missed the $-0.40 estimate on $350,000.00 revenue (est. $1.0M).
+0.1% · S&P 500 +0.6%
EPS of $-0.37 beat the $-0.40 estimate on $0.00 revenue (est. $1.4M).
−5.7% · S&P 500 −4.4%
Where it ended: a close of $15.91 on Nov 19, 2026. Up next: Q4 2026 earnings on Feb 25, 2027 (EPS est. $-0.36, revenue est. $5.1M).
Nothing in the past 12 months.
All RLAY dividend historyReplay the year: the line draws itself and stops at each of the 9 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for RLAY and SPY from Benzinga historical bars. Not investment advice.